Table 1. Clinico-pathological characteristics and CFC-recovery following immunomagnetic cell separation.

Patient	Age	PSA	Prior Treatment	Clinical stage	Gleason/Bone scan mets	No. of cores involved	% core involvement (range)	CD49f CFC-recovery %	CD44 CFC-recovery %	CD133 CFC-recovery %
1	81	50	nil	T3	7/N	10/12	30–100	92 (36/39)	9 (6/69)	2 (1/42)
2	72	478	nil	T3	8/Y	6/6	80–100	89 (25/28)	30 (10/36)	0 (0/20)
3	73	55	AB	T3	8/N	6/12	50–100	96 (25/26)	6 (2/35)	3 (1/40)
4	76	66	nil	T3	9/N	11/12	30–90	86 (61/71)	28 (10/35)	0 (0/46)
5	68	92	nil	T3	9/N	10/12	20–90	90 (52/58)	*	6 (2/36)
Mean ±SD	74±5	148±185						90.6±3.7	18.3±12.5	2.2±2.5

All patients had Gleason score 7 or above, clinical stage T3, and one patient had metastatic disease at presentation. CFC-recovery (defined as the proportion of total CFCs within the positive fraction) was measured for each marker, with CD49f demonstrating the highest recovery.

AB = androgen ablation, SD = standard deviation.

^*sample infected.